



10-20-04

JFW

PATENT
DOCKET NO. JHV-028.01

In re Application of:

Gallagher, M., et al.

Application No: 10/722,357

Art Unit: 1641

Filed: November 24, 2003

Attorney Docket: JHV-028.01


For: Target for Therapy of Cognitive Impairment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Number: EV 327704845 US, postage prepaid, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450 on October 19, 2004.


Kristen M. Williams

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Because this application was filed after June 30, 2003, copies of the U.S. patents are not enclosed. However, a copy of the foreign patent documents and copies of the references are also being submitted.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

- (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- (2) after the period defined in (1) but before the mailing date of a **final action or a notice of allowance** under 37 C.F.R. 1.311, and
- the requisite Statement is below, **OR**
- the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- (3) after the mailing date of a **final action or notice of allowance** but before the payment of the **issue fee**, **AND**
- the requisite Statement is below, **AND**
- the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

If the Examiner has any questions, or if a teleconference would advance the instant application toward allowance, the Examiner is urged to telephone the undersigned at 202-261-7356.

Respectfully Submitted,



Gillian M. Fenton
Reg. No. 36,508
Attorney for Applicant

Date: October 19, 2004

Customer No.: 25181
Patent Group
Foley Hoag LLP
155 Seaport Boulevard
Boston, MA 02210
617-832-1000
617-832-7000 (FAX)

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) JHV-028.01	Application Number 10/722,357
		Applicant Gallagher, Michela et al.	
OCT 19 2004 PATENT AND TRADEMARK OFFICE SEARCHED SERIALIZED INDEXED FILED RECEIVED SEARCHED SERIALIZED INDEXED FILED RECEIVED	Filing Date November 24, 2003	Group Art Unit 1641	

U.S. PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A1	6,489,319 B1	December 3, 2002	Neurotherapeutic Use of Carboxypeptidase Inhibitors			February 14, 2001
A2	6,627,625 B1	September 30, 2003	Treatment of Behavioral Disorders with β -Lactam Compounds			August 16, 2000
A3	6,683,075 B1	January 27, 2004	Cycloalkyl, Lactam, Lactone and Related Compounds, Pharmaceutical Compositions Comprising Same, and Methods for Inhibiting β -Amyloid Peptide Release And/Or Its Synthesis By Use			January 6, 2003

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
B1	WO 2004/076675 A2	10 September 2004	PCT	C12P			

OTHER DOCUMENTS*(Including Author, Title, Date, Pertinent Pages Etc.)*

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.